Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMERICA INCBMRA · Entity 8171 | Director | December 13, 2024 | December 18, 2024 |
| MINERVA SURGICAL INCUTRS · Entity 115564 | Director | June 10, 2022 | June 14, 2022 |
| Renalytix plcRNLX · Entity 7446 | Director | November 20, 2023 | November 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMERICA INC
Report date December 13, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 128,790 |
Reported balance
After 2024-12-13 transaction · row 1
1 source rowRow 1 · 2024-12-13 · Grant · Acquired 85,000 · Balance 128,790 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
MINERVA SURGICAL INC
Report date June 10, 2022 · Filed June 14, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 129,579 |
Reported balance
After 2022-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 49,792 · Balance 129,579 F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. Each RSU award will vest in four equal quarterly installments on the quarterly anniversary of the grant date, subject to the Reporting Person continuing as a service provider through each such date. F2: 79,787 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on February 1, 2022 and with respect to one thirty-sixth of the remaining shares each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. Each RSU award will vest in four equal quarterly installments on the quarterly anniversary of the grant date, subject to the Reporting Person continuing as a service provider through each such date.
F2: 79,787 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on February 1, 2022 and with respect to one thirty-sixth of the remaining shares each month thereafter.
Renalytix plc
Report date November 20, 2023 · Filed November 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-11-19 | Direct | 95,000 |
Reported balance
After 2023-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-20 · Grant · Acquired 95,000 · Balance 95,000 F1: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243). F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).
F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 13,871 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:58 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 13,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418323 · ownership.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012477 · wk-form4_1772146552.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,871 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:09 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 5,701 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014191 · wk-form4_1742512161.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,701 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 00:30 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantCommon stock | 85,000 | $0.31 | $26,350.00 |
DisclosureSEC source: 0001493152-24-050500 · ownership.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 128,790 F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") granted to the reporting person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the one year anniversary of December 13, 2024, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer. Read SEC document |
| December 13, 2023 Filed Dec 14, 2023 22:10 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 75,000 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001493152-23-044907 · ownership.xml · derivative · entry 2 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-12-13 F1 · shares: Options granted to Ms. Coste as part of her Fiscal 2024 Board compensation package. F2 · price: Not Applicable Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:29 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-056478 · doc4.xml · derivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Ordinary Shares · 95,000 shares Expires 2033-11-19 F1 · derivative.exercise_price: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243). F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service. Read SEC document |
| July 06, 2023 Filed Jul 7, 2023 20:28 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 190,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041800 · doc4.xml · derivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Ordinary Shares · 190,000 shares Expires 2033-07-05 F1 · derivative.exercise_price: The exercise price is 1.025 pounds sterling. The U.S. dollar equivalent of the exercise price is $1.301 using the Bank of England rate as of July 6, 2023 (1.00 pound sterling = $1.269). F2 · derivative.exercise_date: One third (1/3rd) of the shares subject to the option award shall vest on July 6, 2024, and one eighth (1/8th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| April 20, 2023 Filed Dec 11, 2023 22:18 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 32,000 | Not disclosed Strike: $1.67 | Not disclosed |
DisclosureSEC source: 0001493152-23-044430 · ownership.xml · derivative · entry 2 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2033-04-20 F1 · shares: Options granted to Ms. Coste in April 2023 as part of her fiscal 2023 Board compensation package. Final issuance was subject to and conditioned upon the approval by stockholders of the 2023 Stock Incentive Plan, which occured on December 7, 2023. F2 · price: Not Applicable Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:36 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 2,190 | $2.96 | $6,482.40 |
DisclosureSEC source: 0001513162-23-000010 · primary_doc.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director · Audit Committee Chairperson 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,790 F1 · kind: Open Market Purchase Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 13:05 UTC | MINERVA SURGICAL INC UTRS · Entity 115564 | GrantCommon Stock | 49,792 | $2.41 | $119,998.72 |
DisclosureSEC source: 0001209191-22-036604 · doc4.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,579 F1 · shares: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. Each RSU award will vest in four equal quarterly installments on the quarterly anniversary of the grant date, subject to the Reporting Person continuing as a service provider through each such date. F1 · balance_after: These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. Each RSU award will vest in four equal quarterly installments on the quarterly anniversary of the grant date, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: 79,787 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on February 1, 2022 and with respect to one thirty-sixth of the remaining shares each month thereafter. Read SEC document |
| December 09, 2021 Filed Dec 10, 2021 22:18 UTC | BIOMERICA INC BRMA · Entity 8171 | GrantNon-qualified stock option · Derivative | 25,000 | Not disclosed Strike: $4.46 | Not disclosed |
DisclosureSEC source: 0001513162-21-000145 · primary_doc.xml · derivative · entry 2 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-09 F2 · price: Not applicable Read SEC document |
| December 10, 2020 Filed Dec 12, 2020 00:57 UTC | BIOMERICA INC BMRA · Entity 8171 | GrantNon-qualified stock option · Derivative | 20,000 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0001513162-20-000238 · primary_doc.xml · derivative · entry 2 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 20,000 shares Expires 2030-12-10 F2 · price: Not applicable Read SEC document |
| October 26, 2020 Filed Oct 27, 2020 22:34 UTC | BIOMERICA INC BMRA · Entity 8171 | PurchaseCommon Stock | 9,100 | $5.45 | $49,595.00 |
DisclosureSEC source: 0001513162-20-000217 · primary_doc.xml · nonDerivative · entry 1 Coste Catherine · CIK 0001821432 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Note 1. Disclosed balance after: 9,100 F1 · ownership.nature: Shares were purchased through spouse's retirement account. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.